From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
Adjusted mean annual costs (€) | |||||
Direct costs | Total | Outpatient costs | Inpatient costs | Medication costs | Other costs |
% zero costs | 0% | 0% | 62% | 0% | 56% |
Group | |||||
A | 7460 [7026 – 7924] | 937 [902 – 973] | 3586 [3201 – 4010] | 2522 [2381 – 2663] | 566 [513 – 628] |
B1 | 7117 [6029 – 8392] | 2570 [2256 – 2866] | 1715 [740 – 3076] | 2144 [1903 – 2409] | 777 [529 – 1049] |
B2 | 6099 [4288 – 8256] | 1061 [763 – 1414] | 2338 [561 – 5288] | 1805 [1388 – 2261] | 876 [319 – 1659] |
Adjusted mean annual costs (€) | |||||
Indirect costs | Human capital approach | Friction costs approach | |||
% zero costs | 26% | 72% | |||
Group | |||||
A | 19,583 [18,451 – 20,803] | 981 [839 – 1138] | |||
B1 | 18,813 [13,632 – 24,716] | 1276 [608 – 2181] | |||
B2 | 16,171 [6194 – 28,316] | 1866 [633 – 3764] |